UT
UTHR
HealthcareUnited Therapeutics
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
7
BuybackBullishPer-CompanyMar 28, 2026
United Therapeutics Authorizes $2B Buyback, Cantor Fitzgerald Raises Price Target to $625
- ▸Authorized new $2 billion stock repurchase program
- ▸Launched $1.5 billion accelerated share repurchase (ASR) via Citibank
- ▸Cantor Fitzgerald raised price target from $525 to $625
- ▸Maintained Overweight rating citing TETON-1 clinical trial potential
- ▸$500 million remaining for discretionary buybacks over 1-year period